Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04787471 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Corneal Crosslinking for Treatment of Corneal Neovascularization

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 years later Jul 15, 2026 → Jul 15, 2029
See other at-risk trials from Price Vision Group

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jul 15, 2026 to Jul 15, 2029 Show 4 more changesShow less
    • Enrollment increased: 62 → 138 participants
    • Study completion pushed from Sep 15, 2026 to Sep 15, 2029
    • Eligibility criteria expanded, about 6 words
    • Publications: details revised at 6 of 6 entries
  2. Primary completion date: Jul 15, 2025 to Jul 15, 2026
    • Study completion date: Sep 15, 2025 to Sep 15, 2026
    v7
  3. Primary completion date: Apr 15, 2025 to Jul 15, 2025
    • Study completion date: Jul 15, 2025 to Sep 15, 2025
    v6
  4. Re-verified, no change to tracked fieldsv5
  5. Primary completion date: Apr 15, 2024 to Apr 15, 2025
    • Study completion date: Jul 15, 2024 to Jul 15, 2025
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Primary completion date: Apr 15, 2023 to Apr 15, 2024
    • Study completion date: Jul 15, 2023 to Jul 15, 2024
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 15, 2021 to May 3, 2021
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
Trial Details
NCT Number NCT04787471
Lead Sponsor Price Vision Group
Collaborators: Cornea Research Foundation of America
Conditions
(from sponsor)		 Corneal Neovascularization
Related terms Corneal Neovascularization
Enrollment 138 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov